Amgen Stock In Trouble, Despite Strong Results

Published 03/22/2018, 01:35 AM

Amgen Inc (NASDAQ:AMGN) reported its full year 2017 results on February 1st. On a non-GAAP basis, the California-based biotech giant earned $12.58 per share, an 8% increase from 2016. But instead of celebrating another year of strong business performance, investors punished Amgen stock, which fell from an all-time high of $201.22 to $168.45 between January 29th and February 9th.

The selloff was probably driven by the company’s earnings miss in the fourth quarter. Or maybe it was the poor guidance for 2018. In our opinion, investors only used these as an excuse to get rid of the stock. The real reason for the decline, we believe, was the market itself, which was already anticipating bad news by the time Amgen’s report became public. Trouble is, the Elliott Wave Principle suggests this was just the beginning of an even bigger pullback.
Amgen Inc Weekly Chart
The weekly price chart of Amgen stock shows that the uptrend from $39.16 to $201.22, which has been under construction for almost 10 years since March 2008, took the shape of a five-wave impulse, labeled (1)-(2)-(3)-(4)-(5). Wave (3) is extended, but the five sub-waves of the ending diagonal pattern in wave (5) are also visible.

The bad news for Amgen stock investors is that according to the Wave principle, this pattern should be followed by a three-wave decline, whose targets lie near the support area of wave (4). Wave (4) ended at $130.09 in late-September, 2015. With the stock currently at $182, we can expect another $50 to disappear from the share price. To reinforce the negative outlook, the MACD indicator shows a bearish divergence between waves (5) and (3). Now let’s take a closer look at Amgen stock’s post-earnings drop.
Amgen Inc 1 Hour Chart

Unfortunately, the hourly chart only tilts the table even more in the bears’ favor, by revealing the impulsive structure of the plunge to $168.45. Impulses point in the direction of the larger sequence, which in this case tell us that Amgen stock’s weakness is likely to continue. The weekly and hourly charts point in the same direction, so as long as the top of wave 5 of (5) at 201.22 holds, the bulls’ resistance remains futile.

Original post

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.